References
1. Bercovitz RS, Josephson CD. Thrombocytopenia and bleeding in
pediatric oncology patients. Hematology Am Soc Hematol Educ
Program. 2012;2012:499-505.
2. Cairo MS. Dose reductions and delays: limitations of myelosuppressive
chemotherapy. Oncology (Williston Park). 2000;14(9 Suppl
8):21-31.
3. Al-Samkari H. Thrombopoietin receptor agonists for
chemotherapy-induced thrombocytopenia: a new solution for an old
problem. Hematology. 2022;2022(1):286-295.
4. Degliuomini MD, Armstrong K, Mauguen A, et al. Chemotherapy-induced
thrombocytopenia in pediatric oncology: Scope of the problem and
opportunities for intervention. Pediatr Blood Cancer. 2022;69(10):e29776.
5. Tarantino MD, Bussel JB, Blanchette VS, et al. Romiplostim in
children with immune thrombocytopenia: a phase 3, randomised,
double-blind, placebo-controlled study. Lancet. 2016;388(10039):45-54.
6. Grainger JD, Locatelli F, Chotsampancharoen T, et al. Eltrombopag for
children with chronic immune thrombocytopenia (PETIT2): a randomised,
multicentre, placebo-controlled trial. Lancet. 2015;386(10004):1649-1658.
7. Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to
standard immunosuppression for aplastic anemia. New England
Journal of Medicine. 2017;376(16):1540-1550.
8. Nagrebetsky A, Al-Samkari H, Davis N, Kuter D, Wiener-Kronish J.
Perioperative thrombocytopenia: evidence, evaluation, and emerging
therapies. British Journal of Anaesthesia. 2019;122(1):19-31.
9. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for
Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C.New England Journal of Medicine. 2007;357(22):2227-2236.
10. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in
patients with chronic immune thrombocytopenic purpura: a double-blind
randomised controlled trial. Lancet. 2008;371(9610):395-403.
11. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or Standard of Care
in Patients with Immune Thrombocytopenia. New England Journal of
Medicine. 2010;363(20):1889-1899.
12. Al-Samkari H, Parnes AD, Goodarzi K, Weitzman JI, Connors JM, Kuter
DJ. A multicenter study of romiplostim for chemotherapy-induced
thrombocytopenia in solid tumors and hematologic malignancies.Haematologica. 2021;106(4):1148-1157.
13. Kuter DJ. Managing thrombocytopenia associated with cancer
chemotherapy. Oncology. 2015;29(4):282-282.
14. Soff GA, Miao Y, Bendheim G, et al. Romiplostim Treatment of
Chemotherapy-Induced Thrombocytopenia. J Clin Oncol. 2019;37(31):2892-2898.
15. Parameswaran R, Lunning M, Mantha S, et al. Romiplostim for
management of chemotherapy-induced thrombocytopenia. Supportive
care in cancer. 2014;22:1217-1222.
16. Mingot-Castellano ME, Reguera-Ortega JL, Zafra Torres D, et al. Use
of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in
Anti-CD19 CAR-T Cell-Treated Patients. J Clin Med. 2024;13(17).
17. Beyar-Katz O, Perry C, On YB, et al. Thrombopoietin receptor agonist
for treating bone marrow aplasia following anti-CD19 CAR-T
cells-single-center experience. Ann Hematol. 2022;101(8):1769-1776.
18. Jacobson AE, Shah N, Setty BA. Romiplostim for therapy-related
thrombocytopenia in pediatric malignancies. Pediatr Blood Cancer. 2017;64(8).
19. Merjaneh N, Young J, Mangoli A, et al. Chemotherapy-induced
thrombocytopenia in Ewing sarcoma: Implications and potential for
romiplostim supportive care. Pediatr Blood Cancer. 2022;69(7):e29548.
20. Fassel H, Bussel JB, Roberts SS, Modak S. Romiplostim for immune
thrombocytopenia in neuroblastoma patients receiving chemotherapy.Journal of pediatric hematology/oncology. 2019;41(4):e257-e259.
21. Griffiths EA, Roy V, Alwan L, et al. NCCN Guidelines® Insights:
Hematopoietic Growth Factors, Version 1.2022: Featured Updates to the
NCCN Guidelines. Journal of the National Comprehensive Cancer
Network. 2022;20(5):436-442.
22. National Institutes of Health NCICTCfAECvhccgpeadCv.
23. Cheng THT, Tsui TKC, Kwok JSS, et al. Comprehensive characterization
and resolution of discrepant spectrophotometric bilirubin results in
patients on eltrombopag therapy. Clinical Chemistry and Laboratory
Medicine (CCLM). 2020;58(10):1713-1723.
24. Poventud-Fuentes I, Garnett E, Despotovic J, Devaraj S. Interference
of eltrombopag with bilirubin measurements on the Vitros 5600 analyzer.J Clin Lab Anal. 2021;35(8):e23796.
25. Mittelman M, Platzbecker U, Afanasyev B, et al. Eltrombopag for
advanced myelodysplastic syndromes or acute myeloid leukaemia and severe
thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2
trial. Lancet Haematol. 2018;5(1):e34-e43.
26. Giagounidis A, Mufti GJ, Fenaux P, et al. Results of a randomized,
double-blind study of romiplostim versus placebo in patients with
low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia.Cancer. 2014;120(12):1838-1846.
27. Corazza F, Hermans C, D’Hondt S, et al. Circulating thrombopoietin
as an in vivo growth factor for blast cells in acute myeloid leukemia.Blood. 2006;107(6):2525-2530.
28. Will B, Kawahara M, Luciano JP, et al. Effect of the nonpeptide
thrombopoietin receptor agonist Eltrombopag on bone marrow cells from
patients with acute myeloid leukemia and myelodysplastic syndrome.Blood. 2009;114(18):3899-3908.
29. Kantarjian H, Fenaux P, Sekeres MA, et al. Safety and efficacy of
romiplostim in patients with lower-risk myelodysplastic syndrome and
thrombocytopenia. J Clin Oncol. 2010;28(3):437-444.
30. Yang Y-L, Jaing T-H, Chen S-H, et al. Treatment outcomes of
pediatric acute myeloid leukemia: a retrospective analysis from 1996 to
2019 in Taiwan. Scientific Reports. 2021;11(1):5893.
31. Hunger SP, Raetz EA. How I treat relapsed acute lymphoblastic
leukemia in the pediatric population. Blood. 2020;136(16):1803-1812.